The present role of echocardiography is generally restricted to screening for pulmonary arterial hypertension (PAH). The aim of our study was to identify new echocardiographic prognostic factors for mortality in PAH which would give this imaging modality a genuine role in patient management.
Introduction
Pulmonary arterial hypertension (PAH) is a rare and serious disease, characterized by increased pulmonary vascular resistance leading to right heart failure and death. PAH is defined as mean pulmonary artery pressure (PAP) .25 mmHg at rest (measured during heart catheterization). 1 Echocardiography should be an investigation of choice for both screening and management of this disease, because of its reliability, harmlessness, and ability to reveal echocardiographic parameters that are predictive of mortality. Although several authors have drawn attention to the key role of echocardiography in the management of PAH, 2, 3 its present role is still a restricted one.
To date, five echocardiographic parameters have been described in the literature as associated with mortality in PAH: degree of pericardial effusion, 4 -6 right atrial area indexed to body surface area, 6 end-diastolic eccentricity index, 6 right ventricular (RV) Tei index, 7 and tricuspid annular plane systolic excursion (TAPSE). 8 Other clinical, biological, haemodynamic, and MRI parameters have also been described. 9 -24 Although numerous treatments have been introduced with subtle improvements in echocardiographic parameters, 25, 26 the prognosis of the disease remains sombre. The clinician needs objective parameters to detect worsening of the patient's condition as early as possible and initiate optimal treatment. In this study, we sought to identify new echocardiographic prognostic factors for mortality and so to define the place of echocardiography in the management of patients with PAH.
Methods and materials Patients
This prospective, single-centre study included from June 2005 to February 2008 all patients followed for PAH in the specialized † Institution where work was performed: CHU Toulouse Rangueil-Larrey, 1 Avenue Jean Poulhes, TSA 50032, 31059 Toulouse Cedex 9, France. centre in our institution. We excluded patients with post-capillary pulmonary hypertension and patients with PAH related to congenital heart disease with shunt. The study was approved by the institutional ethics committee and all subjects gave written informed consent.
Study protocol
At inclusion, we collected data relating to the disease, clinical findings, right heart catheterization and echocardiography findings, and treatment given after the initial evaluation. Patients underwent regular, organized follow-up and individual outcomes were prospectively recorded during follow-up.
All echocardiographic investigations were carried out using an ATL HDI 3500 device (Philips, Bothell, WA, USA) with a 2.5 MHz probe. Data were collected according to a pre-established protocol. The investigator was blinded to the patient's clinical characteristics, treatment, and right heart catheterization findings.
The following echocardiographic data were obtained: † four-chamber apical measurement of the right chambers: 27 enddiastolic and end-systolic RV area (cm 2 ) and determination of fractional shortening of RV area (%) using the equation end À diastolic area À end À systolic area end À systolic area Â 100 † end-diastolic and end-systolic RV volume (mL) with determination of RV ejection fraction (RVEF, %) using Simpson's single plane method in apical four-chamber view, 27 † right atrial area (cm 2 ) in apical four-chamber view, 6 † parameters of RV function: Tei index, 28 TAPSE (mm) 8 with M-mode cursor placed through the lateral tricuspid annulus in apical four-chamber view, † measurement of systolic pulmonary pressure (sPAP) (mmHg) from tricuspid insufficiency flow, of diastolic pulmonary pressure (dPAP) from pulmonary insufficiency flow, and of mean pulmonary pressure (mean PAP) using the equation 1, 27 mean PAP ¼ ðsPAP þ 2dPAPÞ 3 † measurement of inferior vena cava (IVC) diameter (mm) in under-costal view and estimation of right atrial pressure (mmHg) by studying respiratory variations in IVC diameter, 27 † search for pericardial effusion, 5 † four-chamber apical measurement of the left ventricle (LV): end-diastolic and end-systolic LV volume (mL) and end-diastolic and end-systolic eccentricity index by Ryan's method, 29 † analysis of the end-diastolic and end-systolic interventricular septal curve in parasternal short-axis views in two-dimensional mode through the base of the heart. The septal curve was considered normal if it was convex towards the RV and abnormal if it was flattened or convex towards the LV (end-diastole was identified at the start of the R wave on the electrocardiogram in conjunction with echocardiography, and end-systole by selecting the smallest chamber diameter), † measurement of aortic cardiac output (L/min) and cardiac index (L/min/m 2 ). 30 Heart catheterization was done using a standard protocol.
Data analysis
Statistical analysis was performed on SAS w statistical software (version 9.1, SAS Institute, Cary, NC, USA). The study endpoint was mortality. Qualitative variables were first compared between deceased and surviving patients using x 2 and Fisher's exact tests. A non-parametric Wilcoxon's test was used to compare distribution of quantitative variables between deceased and surviving patients. Quantitative variables were then converted into binary qualitative variables for further analyses, using either an accepted threshold from the literature or a discriminating threshold identified by analysis of the receiver operating characteristic curve (the threshold chosen for each variable was the one maximizing sensitivity and specificity for mortality prediction). Kaplan -Meier survival curves were drawn for all qualitative variables significantly associated with the endpoint. The log-rank test was used to compare curves drawn for different levels of an explanatory variable. Lastly, hazard ratios (HRs) for all-cause mortality were estimated based on Cox proportional hazard analysis. HRs were finally adjusted for NYHA class and 6 min walk test (6MWT) distance.
Inter-and intra-observer variability in measurements was assessed on a subsample of 30 patients. Intra-class correlation coefficients were estimated for the echocardiographic parameters.
Results

Patient characteristics
We included 89 patients during the 33 months of the study ( Table 1) . Ten (9.8%) were excluded because their echocardiographic window was of inadequate quality and 79 patients underwent statistical analysis. Of these, 56% were incident cases and 44% were prevalent cases. Median duration of follow-up was 12 months (interquartile interval 5 -21 months).
Median duration of symptoms at diagnosis was 23 months (interquartile interval 12 -48 months).
The causes of pulmonary hypertension, following the Dana Point classification, 31 were group 1, 52 patients (65.8%); group 3, 12 patients (15.2%); group 4, 20 patients (25.3%); group 5, 2 patients (2.5%) (7 patients with two associated possible causes of PAH were counted twice). Distribution by NYHA class at inclusion was class I 1.3%, class II 29%, class III 57%, and class IV 12.7%. Treatments at inclusion are shown in Table 2 , right heart catheterization findings in Table 3 , and echocardiographic findings at inclusion in Table 4 . During follow-up, 16 patients died of their pulmonary disease, a cumulative mortality rate of 20.2% and an incidence of 18 deaths per 100 person-years.
Echocardiographic prognostic factors for mortality
We identified seven echocardiographic variables significantly associated with mortality. Kaplan -Meier survival curves were drawn for each factor (Figure 1) . Results are given as n (%) or median (interquartile interval) (min, max). Results are given as n (%) or median (interquartile interval) (min, max). Results are given as n (%) or median (interquartile interval) (min, max). dPAP, diastolic pulmonary artery pressure; HR, hazard ratio; IVC, inferior vena cava; LV, left ventricular; mPAP, mean pulmonary artery pressure; NO, nitric oxide; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RV, right ventricular; RVEF, right ventricular ejection fraction; SAP, systolic arterial pressure; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; 6MWT, 6 min walk test distance. After adjustment for NYHA class and 6MWT distance, these echocardiographic parameters remained significant ( Table 5) .
Reproducibility of the new prognostic factors
Intra-and inter-observer variability of these factors was good: r ¼ 0.99, P , 0.0001 and r ¼ 0.98, P , 0.0001, respectively, for mean PAP; r ¼ 0.97, P , 0.0001 and r ¼ 0.98, P , 0.0001 for dPAP; r ¼ 0.94, P , 0.0001 and r ¼ 0.98, P , 0.0001 for IVC diameter and respiratory variation in diameter , 50%. Concordance for abnormal end-diastolic septal curve assessment was 100%.
Discussion
Our study reveals four new echocardiographic parameters that are prognostic factors for mortality. We also confirmed the prognostic value of three other parameters previously described in the literature. This is one of the largest series yet published concerning echocardiography and PAH.
Mean PAP and dPAP
As far as we are aware, there has been no published study of mean PAP and dPAP in echocardiographic evaluation of the prognosis of patients with PAH. However, both these parameters have been described as prognostic factors for mortality in right heart catheterization. 4, 6, 32 In our study, sPAP did not appear to be a predictor of mortality, which was in agreement with findings in an earlier series. 7 
Septal curve
We demonstrated that abnormal end-diastolic septal curve was a predictor of mortality. However, abnormal end-systolic septal curve did not appear to be a prognostic factor. These results may be compared with measurement of the eccentricity index described by Ryan et al. 29 as this parameter may be approached indirectly and semi-quantitatively by analysis of the end-systolic and end-diastolic septal curve. Raymond et al. 6 showed that enddiastolic eccentricity index was a prognostic factor for mortality or lung transplantation in univariate analysis in a primary PAH population of NYHA stage III or IV patients included in a therapeutic trial of long-term epoprostenol. In our study, the eccentricity index, whether end-diastolic or end-systolic, did not appear to be a prognostic factor for mortality, unlike end-diastolic septal curve. This is probably due to difficulty of measurement, as qualitatively it is very easy to see an abnormal septal curve. However, the results of both studies still follow the same line, since it is enddiastolic abnormality which seems to predominate as a prognostic factor.
Inferior vena cava
We have shown that an IVC diameter !20 mm with respiratory variation of diameter ,50% was a prognostic factor for mortality. As far as we are aware, no study has previously examined this parameter in PAH, although it is the basis of any echocardiographic investigation and it has good reproducibility. The prognostic value of the IVC is similar to that of right atrial pressure (measured during heart catheterization), as already described in the literature. 4, 6, 32 This factor reflects both volume overload of the right chambers and RV exhaustion.
Tei index
The Tei index, reflecting global RV performance, had already been described as a predictor of mortality in a study by Yeo et value was 0.83, the median of the index observed, whereas in our series the median was 0.90. In our study, we observed that an index !0.98 was significantly associated with mortality, thus providing a new threshold that could be considered whatever the cause of precapillary pulmonary hypertension.
TAPSE
We found that TAPSE was a prognostic factor for mortality, as already demonstrated by Forfia et al. 8 They found a cutoff value of 1.8 cm, but unlike these authors, we observed a higher HR of death associated with lower TAPSE values, without identifying a true threshold. This may be explained by several reasons: in their study, mortality rate reached 37% compared with 20.2% in our series, as the condition of their patients was more serious; also, they included essentially Dana Point group 1 patients (75%), whereas our distribution was more heterogenous. In addition, the cutoff value found in their study was in contradiction with published data on the normal TAPSE value in the general population (1.6 cm) and the close correlation found between TAPSE and isotopic RVEF in the study of Kaul et al., 33 with normal RVEF for a TAPSE value .15 mm.
Pericardial effusion
We demonstrated that pericardial effusion was a prognostic factor for mortality. This agreed with two previous studies that included only patients with idiopathic PAH, 4 one of which comprised only NYHA class III or IV patients. 6 
Limitations
The primary limitation of our study is that it was single centre. However, our series of 79 patients is one of the largest in the literature relating to echocardiography and PAH. In another respect, nearly all the prognostic parameters described in the literature related to patients with idiopathic PAH, making it difficult to extrapolate the findings. In our study, the distribution of patients between the various Dana Point classification groups is not equal, as group 1 patients predominate (65.8%), but this reflects the situation as we found it.
The lack of data such as Doppler tissue imaging 34 and 3D study 27, 35 of the right ventricle may be regretted. However, we considered that it was important in the first instance to validate simple measurements that are used in routine practice and are available in any centre. Another limitation of our study is that we did not take into account any treatment changes during follow-up that could have affected prognosis. However, all patients received regular care and optimal treatment in accordance with current guidelines and practice in our centre.
Lastly, we studied the impact of each prognostic factor after adjusting for NYHA class and 6MWT distance as markers of disease severity. We did not build a model including several echocardiographic parameters as covariates, considering that these variables would be too inter-related because of interaction between the two ventricles.
Conclusion
We demonstrated seven prognostic factors for mortality of which four had not previously been described in the literature, whatever the cause of precapillary PAH. Ultimately, we hope that these findings will aid in choosing echocardiographic criteria to assess severity of PAH, in order to anticipate treatment adjustments without systematic cardiac catheterization.
Echocardiography deserves an important place in diagnosis of patients with PAH. Its role should not be restricted merely to that of a screening investigation.
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